Catharine M L West

List of Publications by Year in Descending Order

244 papers	10,505 citations	57 h-index	90 g-index
272 ext. papers	12,449 ext. citations	5.2 avg, IF	5.81 L-index

#	Paper	IF	Citations
244	Development and Optimization of a Machine-Learning Prediction Model for Acute Desquamation After Breast Radiation Therapy in the Multicenter REQUITE Cohort. *Advances in Radiation Oncology*, **2022**, 7, 100890	3.3	0
243	Development and validation of a hypoxia-associated signature for lung adenocarcinoma.. *Scientific Reports*, **2022**, 12, 1290	4.9	2
242	Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study).. *Lung Cancer*, **2022**, 166, 228-241	5.9	0
241	Pretreatment Lymphocyte Count Predicts Benefit From Concurrent Chemotherapy With Radiotherapy in Oropharyngeal Cancer.. *Journal of Clinical Oncology*, **2022**, JCO2101991	2.2	0
240	The effect of hypoxia on PD-L1 expression in bladder cancer. *BMC Cancer*, **2021**, 21, 1271	4.8	1
239	Immune infiltrate diversity confers a good prognosis in follicular lymphoma. *Cancer Immunology, Immunotherapy*, **2021**, 70, 3573-3585	7.4	1
238	A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer. *British Journal of Cancer*, **2021**, 125, 85-93	8.7	3
237	An evaluation of MR based deep learning auto-contouring for planning head and neck radiotherapy. *Radiotherapy and Oncology*, **2021**, 158, 112-117	5.3	3
236	Lost in application: Measuring hypoxia for radiotherapy optimisation. *European Journal of Cancer*, **2021**, 148, 260-276	7.5	9
235	Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. *Radiotherapy and Oncology*, **2021**, 159, 241-248	5.3	1
234	Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer. *BMC Urology*, **2021**, 21, 96	2.2	1
233	Identifying the Radioresponsive Genome for Genomics-Guided Radiotherapy. *Journal of the National Cancer Institute*, **2021**, 113, 223-224	9.7	2
232	Bladder preservation: Translating discovery for clinical impact in urothelial cancer. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 201-208	2.8	1
231	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. *Nature Genetics*, **2021**, 53, 65-75	36.3	62
230	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2021**, 24, 532-541	6.2	3
229	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. *Nature Communications*, **2021**, 12, 1236	17.4	14
228	Developing Tumor Radiosensitivity Signatures Using LncRNAs. *Radiation Research*, **2021**, 195, 324-333	3.1	3

227	Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399). *International Journal of Radiation Oncology Biology Physics*, **2021**, 110, 1407-1415	4	4
226	A data science approach for early-stage prediction of Patient susceptibility to acute side effects of advanced radiotherapy. *Computers in Biology and Medicine*, **2021**, 135, 104624	7	
225	Impact of hypoxia on cervical cancer outcomes. *International Journal of Gynecological Cancer*, **2021**, 31, 1459-1470	3.5	2
224	The Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. *Cancers*, **2020**, 12,	6.6	4
223	Independence of HIF1a and androgen signaling pathways in prostate cancer. *BMC Cancer*, **2020**, 20, 469	4.8	8
222	Radiobiologically derived biphasic fractionation schemes to overcome the effects of tumour hypoxia. *British Journal of Radiology*, **2020**, 93, 20190250	3.4	0
221	External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort. *Frontiers in Oncology*, **2020**, 10, 575909	5.3	5
220	External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort. *Frontiers in Oncology*, **2020**, 10, 575909	5.3	1
219	Spatial proximity between T and PD-L1 expressing cells as a prognostic biomarker for oropharyngeal squamous cell carcinoma. *British Journal of Cancer*, **2020**, 122, 539-544	8.7	16
218	Selection of endogenous control genes for normalising gene expression data derived from formalin-fixed paraffin-embedded tumour tissue. *Scientific Reports*, **2020**, 10, 17258	4.9	3
217	A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort. *Frontiers in Oncology*, **2020**, 10, 541281	5.3	4
216	Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. *Journal of the National Cancer Institute*, **2020**, 112, 179-190	9.7	32
215	The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists. *International Journal of Radiation Oncology Biology Physics*, **2019**, 105, 698-712	4	38
214	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019**, 10, 431	17.4	45
213	MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer. *International Journal of Radiation Oncology Biology Physics*, **2019**, 104, 809-818	4	17
212	Multi-centre technical evaluation of the radiation-induced lymphocyte apoptosis assay as a predictive test for radiotherapy toxicity. *Clinical and Translational Radiation Oncology*, **2019**, 18, 1-8	4.6	6
211	Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer. *Clinical Cancer Research*, **2019**, 25, 5315-5328	12.9	54
210	REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. *Radiotherapy and Oncology*, **2019**, 138, 59-67	5.3	26

209	Radiogenomics in the Era of Advanced Radiotherapy. *Clinical Oncology*, **2019**, 31, 319-325	2.8	8
208	Guidelines for using sigQC for systematic evaluation of gene signatures. *Nature Protocols*, **2019**, 14, 1377-1400	13.1	14
207	Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. *British Journal of Clinical Pharmacology* , **2019**, 85, 1781-1789	3.8	2
206	Use of a novel atlas for muscles of mastication to reduce inter observer variability in head and neck radiotherapy contouring. *Radiotherapy and Oncology*, **2019**, 130, 56-61	5.3	7
205	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. *Cancer Epidemiology Biomarkers and Prevention*, **2019**, 28, 208-216	4	9
204	Genetic Variants Predict Optimal Timing of Radiotherapy to Reduce Side-effects in Breast Cancer Patients. *Clinical Oncology*, **2019**, 31, 9-16	2.8	17
203	Acute Epithelial Toxicity Is Prognostic for Improved Prostate Cancer Response to Radiation Therapy: A Retrospective, Multicenter, Cohort Study. *International Journal of Radiation Oncology Biology Physics*, **2018**, 101, 957-963	4	4
202	The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma. *British Journal of Cancer*, **2018**, 118, 698-704	8.7	10
201	A new approach for modeling patient overall radiosensitivity and predicting multiple toxicity endpoints for breast cancer patients. *Acta Oncologica*, **2018**, 57, 604-612	3.2	3
200	Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. *EBioMedicine*, **2018**, 31, 182-189	8.8	67
199	Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference. *International Journal of Radiation Oncology Biology Physics* , **2018**, 101, 274-284	4	29
198	Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome. *Journal of the National Cancer Institute*, **2018**, 110,	9.7	124
197	Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy. *PLoS ONE*, **2018**, 13, e0194841	3.7	5
196	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nature Genetics*, **2018**, 50, 928-936	36.3	340
195	Radiation biology and oncology in the genomic era. *British Journal of Radiology*, **2018**, 91, 20170949	3.4	12
194	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. *Nature Communications*, **2018**, 9, 2256	17.4	57
193	Radiogenomic Predictors of Adverse Effects following Charged Particle Therapy. *International Journal of Particle Therapy*, **2018**, 5, 103-113	1.5	5
192	Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status. *Journal of Cancer Research and Clinical Oncology*, **2018**, 144, 389-401	4.9	3

191	Validation of a hypoxia related gene signature in multiple soft tissue sarcoma cohorts. *Oncotarget*, **2018**, 9, 3946-3955	3.3	18
190	Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting monocarboxylate transporters. *Scientific Reports*, **2018**, 8, 16804	4.9	21
189	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. *Nature Communications*, **2018**, 9, 4616	17.4	30
188	Ionizing radiation biomarkers in epidemiological studies - An update. *Mutation Research - Reviews in Mutation Research*, **2017**, 771, 59-84	7	90
187	The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). *British Journal of Cancer*, **2017**, 116, 649-657	8.7	6
186	A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients. *Clinical Cancer Research*, **2017**, 23, 4761-4768	12.9	70
185	The prognostic value of dynamic contrast-enhanced MRI contrast agent transfer constant K in cervical cancer is explained by plasma flow rather than vessel permeability. *British Journal of Cancer* , **2017**, 116, 1436-1443	8.7	18
184	Radiogenomics and radiotherapy response modeling. *Physics in Medicine and Biology*, **2017**, 62, R179-R206	3.8	33
183	Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era. *Frontiers in Oncology*, **2017**, 7, 83	5.3	22
182	Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic. *Oncotarget*, **2017**, 8, 14416-14427	3.3	54
181	HPV-Related Oropharynx Cancer in the United Kingdom: An Evolution in the Understanding of Disease Etiology. *Cancer Research*, **2016**, 76, 6598-6606	10.1	95
180	Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. *Radiotherapy and Oncology*, **2016**, 121, 431-439	5.3	69
179	Improved accuracy and precision of tracer kinetic parameters by joint fitting to variable flip angle and dynamic contrast enhanced MRI data. *Magnetic Resonance in Medicine*, **2016**, 76, 1270-81	4.4	8
178	Patients with a High Polygenic Risk of Breast Cancer do not have An Increased Risk of Radiotherapy Toxicity. *Clinical Cancer Research*, **2016**, 22, 1413-20	12.9	11
177	Phosphatidylinositide 3-kinase (PI3K) and PI3K-related kinase (PIKK) activity contributes to radioresistance in thyroid carcinomas. *Oncotarget*, **2016**, 7, 63106-63123	3.3	9
176	Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement. *Radiotherapy and Oncology*, **2016**, 121, 440-446	5.3	7
175	Radiogenomics: A systems biology approach to understanding genetic risk factors for radiotherapy toxicity?. *Cancer Letters*, **2016**, 382, 95-109	9.9	50
174	Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity. *British Journal of Cancer*, **2016**, 114, 1165-74	8.7	12

173	Pitfalls in Prediction Modeling for Normal Tissue Toxicity in Radiation Therapy: An Illustration With the Individual Radiation Sensitivity and Mammary Carcinoma Risk Factor Investigation Cohorts. *International Journal of Radiation Oncology Biology Physics*, **2016**, 95, 1466-1476	4	9
172	Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. *EBioMedicine*, **2016**, 10, 150-63	8.8	50
171	Incorporating Genetic Biomarkers into Predictive Models of Normal Tissue Toxicity. *Clinical Oncology*, **2015**, 27, 579-87	2.8	28
170	Tumor plasma flow determined by dynamic contrast-enhanced MRI predicts response to induction chemotherapy in head and neck cancer. *Oral Oncology*, **2015**, 51, 508-13	4.4	13
169	XRCC1 Polymorphism Associated With Late Toxicity After Radiation Therapy in Breast Cancer Patients. *International Journal of Radiation Oncology Biology Physics*, **2015**, 92, 1084-1092	4	53
168	FOXM1 and polo-like kinase 1 are co-ordinately overexpressed in patients with gastric adenocarcinomas. *BMC Research Notes*, **2015**, 8, 676	2.3	9
167	Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Oncology, The*, **2015**, 16, 1515-1524	21.7	74
166	Imaging tumour hypoxia with positron emission tomography. *British Journal of Cancer*, **2015**, 112, 238-50	8.7	210
165	Prognostic value of hypoxia-associated markers in advanced larynx and hypopharynx squamous cell carcinoma. *Laryngoscope*, **2015**, 125, E8-15	3.6	15
164	Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle-invasive bladder cancer. *International Journal of Cancer*, **2015**, 136, 709-20	7.5	18
163	FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2014**, 464, 145-56	5.1	41
162	STROGAR - STrengthening the Reporting Of Genetic Association studies in Radiogenomics. *Radiotherapy and Oncology*, **2014**, 110, 182-8	5.3	47
161	A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. *Nature Genetics*, **2014**, 46, 891-4	36.3	92
160	Dynamic contrast-enhanced magnetic resonance imaging biomarkers in head and neck cancer: potential to guide treatment? A systematic review. *Oral Oncology*, **2014**, 50, 963-70	4.4	63
159	NIMRAD - a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer. *Clinical Oncology*, **2014**, 26, 344-7	2.8	42
158	A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. *Radiotherapy and Oncology*, **2014**, 111, 178-85	5.3	102
157	Radiogenomics: the search for genetic predictors of radiotherapy response. *Future Oncology*, **2014**, 10, 2391-406	3.6	54
156	Expression of hypoxia-inducible factor-1 predicts benefit from hypoxia modification in invasive bladder cancer. *British Journal of Cancer*, **2014**, 111, 437-43	8.7	31

155	Investigation of the epithelial to mesenchymal transition markers S100A4, vimentin and Snail1 in gastroesophageal junction tumors. *Ecological Management and Restoration*, **2014**, 27, 485-92	3	6
154	Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study. *Translational Oncology*, **2014**, 7, 55-64	4.9	15
153	Investigation of radiosensitivity gene signatures in cancer cell lines. *PLoS ONE*, **2014**, 9, e86329	3.7	34
152	The REQUITE project: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side effects.. *Journal of Clinical Oncology*, **2014**, 32, 276-276	2.2	
151	Molecular and cellular processes underlying the hallmarks of head and neck cancer. *European Archives of Oto-Rhino-Laryngology*, **2013**, 270, 2585-93	3.5	25
150	The prognostic significance of the biomarker p16 in oropharyngeal squamous cell carcinoma. *Clinical Oncology*, **2013**, 25, 630-8	2.8	42
149	A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. *Clinical Cancer Research*, **2013**, 19, 4879-88	12.9	143
148	FTIR microspectroscopy of selected rare diverse sub-variants of carcinoma of the urinary bladder. *Journal of Biophotonics*, **2013**, 6, 73-87	3.1	33
147	An in vivo hypoxia metagene identifies the novel hypoxia inducible factor target gene SLCO1B3. *European Journal of Cancer*, **2013**, 49, 1741-51	7.5	13
146	Poor prognosis associated with human papillomavirus genotypes in cervical carcinoma cannot be explained by intrinsic radiosensitivity. *International Journal of Radiation Oncology Biology Physics* , **2013**, 85, e223-9	4	6
145	Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial. *Radiotherapy and Oncology*, **2013**, 108, 40-7	5.3	45
144	Prospective technical validation and assessment of intra-tumour heterogeneity of a low density array hypoxia gene profile in head and neck squamous cell carcinoma. *European Journal of Cancer*, **2013**, 49, 156-65	7.5	28
143	Lack of prognostic effect of carbonic anhydrase-9, hypoxia inducible factor-1and bcl-2 in 286 patients with early squamous cell carcinoma of the glottic larynx treated with radiotherapy. *Clinical Oncology*, **2013**, 25, 59-65	2.8	19
142	Susuk charms? A case report. *British Dental Journal*, **2013**, 215, 13-5	1.2	6
141	A pilot study to investigate the role of thymidylate synthase as a marker of prognosis for neoadjuvant chemotherapy in gastric and gastro-oesophageal junction adenocarcinoma. *Gastroenterology Research and Practice*, **2013**, 2013, 502153	2	3
140	The case for including bowel urgency in toxicity reporting after pelvic cancer treatment. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2013**, 11, 827-33	7.3	2
139	Genome-wide association studies and prediction of normal tissue toxicity. *Seminars in Radiation Oncology*, **2012**, 22, 91-9	5.5	22
138	Will SNPs be useful predictors of normal tissue radiosensitivity in the future?. *Radiotherapy and Oncology*, **2012**, 105, 283-8	5.3	17

137	Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. *Lancet Oncology, The*, **2012**, 13, 65-77	21.7	161
136	Standardized Total Average Toxicity score: a scale- and grade-independent measure of late radiotherapy toxicity to facilitate pooling of data from different studies. *International Journal of Radiation Oncology Biology Physics*, **2012**, 82, 1065-74	4	49
135	Osteoradionecrosis in head-and-neck cancer has a distinct genotype-dependent cause. *International Journal of Radiation Oncology Biology Physics*, **2012**, 82, 1479-84	4	21
134	Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. *Radiotherapy and Oncology*, **2012**, 105, 289-95	5.3	52
133	Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation. *British Journal of Cancer*, **2012**, 107, 684-94	8.7	101
132	A replicated association between polymorphisms near TNF and risk for adverse reactions to radiotherapy. *British Journal of Cancer*, **2012**, 107, 748-53	8.7	55
131	Lysyl oxidase: from basic science to future cancer treatment. *Cell Structure and Function*, **2012**, 37, 75-80	2.2	75
130	Statistical considerations of optimal study design for human plasma proteomics and biomarker discovery. *Journal of Proteome Research*, **2012**, 11, 2103-13	5.6	45
129	Tissue factor expression in the metaplasia-adenoma-carcinoma sequence of gastric cancer in a European population. *British Journal of Cancer*, **2012**, 107, 1125-30	8.7	11
128	The FOXM1-PLK1 axis is commonly upregulated in oesophageal adenocarcinoma. *British Journal of Cancer*, **2012**, 107, 1766-75	8.7	29
127	Development and validation of a nomogram for prediction of survival and local control in laryngeal carcinoma patients treated with radiotherapy alone: a cohort study based on 994 patients. *Radiotherapy and Oncology*, **2011**, 100, 108-15	5.3	45
126	Perfusion estimated with rapid dynamic contrast-enhanced magnetic resonance imaging correlates inversely with vascular endothelial growth factor expression and pimonidazole staining in head-and-neck cancer: a pilot study. *International Journal of Radiation Oncology Biology Physics*, **2011**, 81, 1176-83	4	58
125	Head and neck cancer-part 1: epidemiology, presentation, and preservation. *Clinical Otolaryngology* , **2011**, 36, 65-8	1.8	43
124	The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. *British Journal of Cancer*, **2011**, 104, 1168-77	8.7	217
123	Exon-array profiling unlocks clinically and biologically relevant gene signatures from formalin-fixed paraffin-embedded tumour samples. *British Journal of Cancer*, **2011**, 104, 971-81	8.7	28
122	Mitochondrial DNA mutations in head and neck cancer are infrequent and lack prognostic utility. *British Journal of Cancer*, **2011**, 104, 1319-24	8.7	24
121	Genetics and genomics of radiotherapy toxicity: towards prediction. *Genome Medicine*, **2011**, 3, 52	14.4	118
120	Tumour budding and a low host inflammatory response are associated with a poor prognosis in oesophageal and gastro-oesophageal junction cancers. *Histopathology*, **2010**, 56, 893-9	7.3	58

119	Enhancing fraction measured using dynamic contrast-enhanced MRI predicts disease-free survival in patients with carcinoma of the cervix. *British Journal of Cancer*, **2010**, 102, 23-6	8.7	47
118	Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. *British Journal of Cancer*, **2010**, 102, 428-35	8.7	282
117	Spectral clustering of microarray data elucidates the roles of microenvironment remodeling and immune responses in survival of head and neck squamous cell carcinoma. *Journal of Clinical Oncology*, **2010**, 28, 2881-8	2.2	64
116	Use of multiple biological markers in radiotherapy-treated head and neck cancer. *Journal of Laryngology and Otology*, **2010**, 124, 650-8	1.8	7
115	Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. *Journal of Clinical Investigation*, **2010**, 120, 2842-57	15.9	74
114	Head and neck cancer--Part 1: Epidemiology, presentation, and prevention. *BMJ, The*, **2010**, 341, c4684	5.9	160
113	Head and neck cancer--Part 2: Treatment and prognostic factors. *BMJ, The*, **2010**, 341, c4690	5.9	56
112	Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas. *Endocrine-Related Cancer*, **2010**, 17, 61-72	5.7	75
111	No association between SNPs regulating TGF-1 secretion and late radiotherapy toxicity to the breast: results from the RAPPER study. *Radiotherapy and Oncology*, **2010**, 97, 9-14	5.3	47
110	Establishment of a radiogenomics consortium. *Radiotherapy and Oncology*, **2010**, 94, 117-8	5.3	48
109	Development of a patient-reported questionnaire for collecting toxicity data following prostate brachytherapy. *Radiotherapy and Oncology*, **2010**, 97, 136-42	5.3	20
108	hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. *Cancer*, **2010**, 116, 2148-58	6.4	193
107	A comparison of tracer kinetic models for T1-weighted dynamic contrast-enhanced MRI: application in carcinoma of the cervix. *Magnetic Resonance in Medicine*, **2010**, 63, 691-700	4.4	84
106	Establishment of a Radiogenomics Consortium. *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, 1295-6	4	98
105	Computed tomography overestimation of esophageal tumor length: Implications for radiotherapy planning. *World Journal of Gastrointestinal Oncology*, **2010**, 2, 197-204	3.4	15
104	Genetic Predictors of Normal Tissue Response to Radiotherapy **2010**, 127-135		1
103	Clinical impact of tumour involvement of the anastomotic doughnut in oesophagogastric cancer surgery. *Annals of the Royal College of Surgeons of England*, **2009**, 91, 195-200	1.4	3
102	Blood flow and Vd (water): both biomarkers required for interpreting the effects of vascular targeting agents on tumor and normal tissue. *Molecular Cancer Therapeutics*, **2009**, 8, 303-9	6.1	22

101	The radiobiology/radiation protection interface in healthcare. *Journal of Radiological Protection*, **2009**, 29, A1-A20	1.2	11
100	The degree of circumferential tumour involvement as a prognostic factor in oesophageal cancer. *European Journal of Cardio-thoracic Surgery*, **2009**, 36, 368-73	3	15
99	Exon array analysis of head and neck cancers identifies a hypoxia related splice variant of LAMA3 associated with a poor prognosis. *PLoS Computational Biology*, **2009**, 5, e1000571	5	33
98	Comparison of predicted and clinical response to radiotherapy: a radiobiology modelling study. *Acta Oncologica*, **2009**, 48, 584-90	3.2	8
97	Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. *Nature Reviews Cancer*, **2009**, 9, 134-42	31.3	450
96	Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel biomarker of oxygenation changes in solid tumors. *International Journal of Radiation Oncology Biology Physics*, **2009**, 75, 1209-15	4	95
95	Point: why choose pulsed-dose-rate brachytherapy for treating gynecologic cancers?. *Brachytherapy* , **2009**, 8, 269-72	2.4	5
94	Measurement tools for gastrointestinal symptoms in radiation oncology. *Current Opinion in Supportive and Palliative Care*, **2009**, 3, 36-40	2.6	20
93	Assessment of Drug Resistance in Anticancer Therapy by Nuclear Imaging **2009**, 295-313		0
92	Hypoxia-associated markers in gastric carcinogenesis and HIF-2alpha in gastric and gastro-oesophageal cancer prognosis. *British Journal of Cancer*, **2008**, 98, 965-73	8.7	25
91	Epidermal growth factor receptor-targeted therapy. *British Journal of Radiology*, **2008**, 81 Spec No 1, S36-44	3.4	21
90	Prognostic significance of tumor hypoxia inducible factor-1alpha expression for outcome after radiotherapy in oropharyngeal cancer. *International Journal of Radiation Oncology Biology Physics*, **2008**, 72, 1551-9	4	47
89	The genomics revolution and radiotherapy. *Clinical Oncology*, **2007**, 19, 470-80	2.8	44
88	Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. *International Journal of Radiation Oncology Biology Physics*, **2007**, 67, 84-90	4	67
87	Tumor expression of major vault protein is an adverse prognostic factor for radiotherapy outcome in oropharyngeal carcinoma. *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, 133-40	4	16
86	Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. *British Journal of Cancer*, **2007**, 96, 95-103	8.7	88
85	Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. *British Journal of Cancer*, **2007**, 96, 1377-83	8.7	42
84	Clinical and biological factors affecting response to radiotherapy in patients with head and neck cancer: a review. *Clinical Otolaryngology*, **2007**, 32, 337-45	1.8	26

83	Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. *Cancer Research*, **2007**, 67, 3441-9	10.1	257
82	Exploiting sample variability to enhance multivariate analysis of microarray data. *Bioinformatics*, **2007**, 23, 2733-40	7.2	4
81	Translational research in radiotherapy trials. *British Journal of Radiology*, **2006**, 79, 716-8	3.4	2
80	Hypoxia in head and neck cancer. *British Journal of Radiology*, **2006**, 79, 791-8	3.4	68
79	The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study. *Radiotherapy and Oncology*, **2006**, 80, 123-31	5.3	91
78	No relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervix. *British Journal of Cancer*, **2006**, 94, 115-20	8.7	6
77	Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. *International Journal of Radiation Oncology Biology Physics*, **2006**, 66, 331-8	4	41
76	Imaging vascular physiology to monitor cancer treatment. *Critical Reviews in Oncology/Hematology*, **2006**, 58, 95-113	7	48
75	Is the hypoxia-inducible factor pathway important in gastric cancer?. *European Journal of Cancer*, **2005**, 41, 2792-805	7.5	65
74	Thoracic radiation therapy for limited-stage small-cell lung cancer: unanswered questions. *Clinical Lung Cancer*, **2005**, 7, 23-9	4.9	16
73	Thoracic radiotherapy for limited-stage small-cell lung cancer: controversies and future developments. *Clinical Oncology*, **2005**, 17, 591-8	2.8	20
72	Expression of the proapoptotic protein Bid is an adverse prognostic factor for radiotherapy outcome in carcinoma of the cervix. *British Journal of Cancer*, **2005**, 92, 449-58	8.7	13
71	The potential of PET to increase understanding of the biological basis of tumour and normal tissue response to radiotherapy. *British Journal of Radiology*, **2005**, Supplement_28, 50-54	3.4	4
70	Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. *Clinical Cancer Research*, **2004**, 10, 8405-12	12.9	112
69	The potential of positron-emission tomography to study anticancer-drug resistance. *Nature Reviews Cancer*, **2004**, 4, 457-69	31.3	32
68	Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2004**, 1705, 91-102	11.2	7
67	Cytotoxicity of the bioreductive agent RH1 and its lack of interaction with radiation. *Radiotherapy and Oncology*, **2004**, 70, 311-7	5.3	6
66	Combretastatin A4 phosphate. *Anti-Cancer Drugs*, **2004**, 15, 179-87	2.4	89

65	Positron emission tomography (PET) and anticancer drug development. *Discovery Medicine*, **2004**, 4, 303-6	2.5	
64	GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. *International Journal of Cancer*, **2003**, 104, 85-91	7.5	191
63	Evaluation of the LENT-SOMA scales for the prospective assessment of treatment morbidity in cervical carcinoma. *International Journal of Radiation Oncology Biology Physics*, **2003**, 56, 502-10	4	46
62	Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma?. *British Journal of Cancer*, **2003**, 89, 870-6	8.7	90
61	Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. *Radiotherapy and Oncology*, **2003**, 67, 35-44	5.3	124
60	Assessment of morbidity in carcinoma of the cervix: a comparison of the LENT SOMA scales and the Franco-Italian glossary. *Radiotherapy and Oncology*, **2003**, 69, 195-200	5.3	32
59	Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. *International Journal of Radiation Oncology Biology Physics*, **2002**, 54, 759-67	4	153
58	Short report: a morbidity scoring system for Clinical Oncology practice: questionnaires produced from the LENT SOMA scoring system. *Clinical Oncology*, **2002**, 14, 68-9	2.8	22
57	Late radiation morbidity in a patient with carcinoma of the cervix. *Clinical Oncology*, **2002**, 14, 437-41	2.8	
56	Differential expression of cytokine genes in fibroblasts derived from skin biopsies of patients who developed minimal or severe normal tissue damage after radiotherapy. *Radiation Research*, **2002**, 157, 243-8	3.1	29
55	Relationship between residual radiation-induced DNA double-strand breaks in cultured fibroblasts and late radiation reactions: a comparison of training and validation cohorts of breast cancer patients. *Radiotherapy and Oncology*, **2002**, 62, 321-6	5.3	20
54	Chromosomal radiosensitivity in young cancer patients: possible evidence of genetic predisposition. *International Journal of Radiation Biology*, **2002**, 78, 341-6	2.9	44
53	Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma. *International Journal of Radiation Oncology Biology Physics*, **2001**, 49, 581-6	4	73
52	Radiation response and cure rate of human colon adenocarcinoma spheroids of different size: the significance of hypoxia on tumor control modelling. *International Journal of Radiation Oncology Biology Physics*, **2001**, 49, 1109-18	4	30
51	Ability to undergo apoptosis does not correlate with the intrinsic radiosensitivity (SF2) of human cervix tumor cell lines. *International Journal of Radiation Oncology Biology Physics*, **2001**, 50, 503-9	4	16
50	Incorporating biologic measurements (SF(2), CFE) into a tumor control probability model increases their prognostic significance: a study in cervical carcinoma treated with radiation therapy. *International Journal of Radiation Oncology Biology Physics*, **2001**, 50, 1113-22	4	43
49	Chromosomal radiosensitivity as a marker of predisposition to common cancers?. *British Journal of Cancer*, **2001**, 84, 892-6	8.7	79
48	Lymphocyte radiosensitivity is a significant prognostic factor for morbidity in carcinoma of the cervix. *International Journal of Radiation Oncology Biology Physics*, **2001**, 51, 10-5	4	62

47	Relationships between clonogenic cell survival, DNA damage and chromosomal radiosensitivity in nine human cervix carcinoma cell lines. *International Journal of Radiation Biology*, **2001**, 77, 295-302	2.9	24
46	Pretreatment plasma TGF beta 1 levels are prognostic for survival but not morbidity following radiation therapy of carcinoma of the cervix. *International Journal of Radiation Oncology Biology Physics*, **2000**, 48, 991-5	4	22
45	Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers. *International Journal of Radiation Oncology Biology Physics*, **2000**, 46, 13-9	4	93
44	Expression of Ku70 correlates with survival in carcinoma of the cervix. *British Journal of Cancer*, **2000**, 83, 1702-6	8.7	78
43	Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. *Radiotherapy and Oncology*, **2000**, 57, 53-9	5.3	190
42	Lack of correlation between residual radiation-induced DNA damage, in keratinocytes assayed directly from skin, and late radiotherapy reactions in breast cancer patients. *International Journal of Radiation Oncology Biology Physics*, **1999**, 43, 481-7	4	13
41	A high ratio of apoptosis to proliferation correlates with improved survival after radiotherapy for cervical adenocarcinoma. *International Journal of Radiation Oncology Biology Physics*, **1999**, 44, 507-12	4	28
40	Changes in oxygenation during radiotherapy in carcinoma of the cervix. *International Journal of Radiation Oncology Biology Physics*, **1999**, 45, 119-26	4	45
39	The immunohistochemical expression of DNA-PKCS and Ku (p70/p80) in head and neck cancers: relationships with radiosensitivity. *International Journal of Radiation Oncology Biology Physics*, **1999**, 45, 1005-10	4	28
38	The lack of correlation between proliferation (Ki-67, PCNA, LI, Tpot), p53 expression and radiosensitivity for head and neck cancers. *British Journal of Cancer*, **1999**, 80, 1400-4	8.7	17
37	Tumour vascularity is a significant prognostic factor for cervix carcinoma treated with radiotherapy: independence from tumour radiosensitivity. *British Journal of Cancer*, **1999**, 81, 354-8	8.7	37
36	Prognostic significance of c-erbB-2 protein expression in carcinoma of the cervix treated with radiotherapy. *Journal of Cancer Research and Clinical Oncology*, **1999**, 125, 96-100	4.9	21
35	A correlation between residual radiation-induced DNA double-strand breaks in cultured fibroblasts and late radiotherapy reactions in breast cancer patients. *Radiotherapy and Oncology*, **1999**, 51, 55-65	5.3	46
34	The potential benefit from individualised radiotherapy scheduling for head and neck tumours on the basis of both histological grade and kinetics. *Radiotherapy and Oncology*, **1999**, 51, 109-11	5.3	12
33	Discrimination of human tumor radioresponsiveness using low-dose rate irradiation. *International Journal of Radiation Oncology Biology Physics*, **1998**, 42, 1147-53	4	3
32	The radiosensitivity of human fibroblast cell lines correlates with residual levels of DNA double-strand breaks. *Radiotherapy and Oncology*, **1998**, 47, 271-6	5.3	33
31	The intrinsic radiosensitivity of normal and tumour cells. *International Journal of Radiation Biology*, **1998**, 73, 409-13	2.9	45
30	The biology of photodynamic therapy. *Physics in Medicine and Biology*, **1997**, 42, 913-35	3.8	82

29	Cellular radiosensitivity in human severe-combined-immunodeficiency (SCID) syndromes. *Radiotherapy and Oncology*, **1997**, 42, 53-7	5.3	8
28	A correlation between residual DNA double-strand breaks and clonogenic measurements of radiosensitivity in fibroblasts from preradiotherapy cervix cancer patients. *International Journal of Radiation Oncology Biology Physics*, **1997**, 39, 1137-44	4	27
27	The intrinsic radiosensitivity of cervical carcinoma: correlations with clinical data. *International Journal of Radiation Oncology Biology Physics*, **1995**, 31, 841-6	4	49
26	A comparison of the radiosensitivity of lymphocytes from normal donors, cancer patients, individuals with ataxia-telangiectasia (A-T) and A-T heterozygotes. *International Journal of Radiation Biology*, **1995**, 68, 197-203	2.9	78
25	Implications of delayed reproductive cell death (lethal mutations/genomic instability) for the interpretation of tissue responses. *International Journal of Radiation Biology*, **1995**, 68, 363-7	2.9	9
24	Relationships between the cytotoxic effects of restriction endonucleases and radiation on mammalian cells. *International Journal of Radiation Biology*, **1995**, 67, 327-34	2.9	3
23	Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. *Radiotherapy and Oncology*, **1995**, 37, 1-9	5.3	136
22	Apoptosis as predictor of response to radiotherapy in cervical carcinoma. *Lancet, The*, **1994**, 344, 472	40	42
21	Tumour stem cells: the relevance of predictive assays for tumour control after radiotherapy. *Radiotherapy and Oncology*, **1994**, 30, 11-6	5.3	24
20	Prediction of radiotherapy response using SF2: is it methodology or mythology?. *Radiotherapy and Oncology*, **1994**, 31, 86-8	5.3	6
19	Use of low-dose rate irradiation to measure the intrinsic radiosensitivity of human T-lymphocytes. *International Journal of Radiation Biology*, **1993**, 64, 375-83	2.9	31
18	Use of an internal standard in comparative measurements of the intrinsic radiosensitivities of human T-lymphocytes. *International Journal of Radiation Biology*, **1993**, 64, 385-91	2.9	24
17	A potential pitfall in the use of electroporation: cellular radiosensitization by pulsed high-voltage electric fields. *International Journal of Radiation Biology*, **1992**, 61, 329-34	2.9	12
16	Mechanisms behind the resistance of spheroids to photodynamic treatment: a flow cytometry study. *Photochemistry and Photobiology*, **1992**, 55, 425-30	3.6	17
15	Low-density lipoprotein uptake and the sensitivity to photodynamic treatment of cultured endothelial cells. *International Journal of Radiation Biology*, **1991**, 60, 25-8	2.9	4
14	Comparison of two methods to assess tumour vasculature in human cervical carcinoma. *International Journal of Radiation Biology*, **1991**, 60, 169-73	2.9	3
13	The lower radiosensitivity of mouse kidney cells irradiated in vivo than in vitro: a cell contact effect phenomenon. *International Journal of Radiation Oncology Biology Physics*, **1991**, 20, 1243-8	4	16
12	Prediction of cervical carcinoma response to radiotherapy. *Lancet, The*, **1991**, 338, 818	40	47

11	A comparison of the sensitivity to photodynamic treatment of endothelial and tumour cells in different proliferative states. *International Journal of Radiation Biology*, **1990**, 58, 145-56	2.9	46
10	Additive interaction between tamoxifen and rifampicin in human biliary tract carcinoma cells. *Cancer Letters*, **1990**, 55, 159-63	9.9	8
9	Radiosensitivity testing of primary cervical carcinoma: evaluation of intra- and inter-tumour heterogeneity. *Radiotherapy and Oncology*, **1990**, 18, 349-56	5.3	66
8	Evaluation of surviving fraction at 2 Gy as a potential prognostic factor for the radiotherapy of carcinoma of the cervix. *International Journal of Radiation Biology*, **1989**, 56, 761-5	2.9	67
7	The photodynamic effects of photofrin II, hematoporphyrin derivative, hematoporphyrin, and tetrasodium-mesotetra(4-sulfonatophenyl)porphine in vitro: clonogenic cell survival and drug uptake studies. *Photochemistry and Photobiology*, **1989**, 49, 169-74	3.6	21
6	Flow cytometric analysis of intracellular hematoporphyrin derivative in human tumor cells and multicellular spheroids. *Photochemistry and Photobiology*, **1989**, 50, 665-9	3.6	13
5	Growth phase related variation in the radiation sensitivity of human colon adenocarcinoma cells. *International Journal of Radiation Oncology Biology Physics*, **1988**, 14, 1213-9	4	15
4	Cell survival characteristics of a human colon adenocarcinoma cell line after photodynamic treatment: a comparison of Photofrin II and TPPS. *International Journal of Radiation Biology*, **1988**, 54, 621-34	2.9	26
3	The Radiation Response of a Human Colon Adenocarcinoma Grown in Monolayer, as Spheroids, and in Nude Mice. *Radiation Research*, **1987**, 112, 105	3.1	28
2	A comparison of adriamycin and mAMSA. II. Studies with V79 and human tumour multicellular spheroids. *Cancer Chemotherapy and Pharmacology*, **1987**, 20, 109-14	3.5	5
1	A radiobiological comparison of human tumor soft-agar clonogenic assays. *International Journal of Cancer*, **1986**, 37, 897-903	7.5	26